---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-086214"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T17:43:14.757668+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oramed restructures Scilex debt: exchanges $25M note for convertible notes, warrants, and royalty

## Summary
- Oramed exchanged $22.5M of its Scilex note for a $25M 5.5% convertible note due 2026 and 3.75M warrants at $1.09.
- Oramed exchanged $2.5M of note for a 4.0% royalty on global net sales of ZTlido and SP-103.
- Oramed entered binding term sheet for 50% JV with other investors to license lidocaine products outside US, investing $200K/year.
- Transactions closed Oct 8, 2024; proceeds repaid $12.5M of Oramed's note and eCapital credit facility.
- Scilex issued $50M aggregate convertible notes to Oramed and other investors; Oramed bought $22.5M of that.

## SEC filing metadata
- accession: 0001213900-24-086214
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390024086214/0001213900-24-086214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390024086214/ea0216936-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-086214
- JSON: https://secwatch.observer/filing/0001213900-24-086214.json
- Plain text: https://secwatch.observer/filing/0001213900-24-086214.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.